서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 241 to 300 of 339

Issue DateTitle / Author(s) / CitationFileAltmetrics
2020-02
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
view fileDOI
2020-02
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
DOI
2020-02
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
DOI
2020-02
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
DOI
2020-02
Corrigendum to Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies (The Breast (2018) 41(S1) (S11–S12), (S0960977618301760), (10.1016/j.breast.2018.08.033))
DOI
2020-03
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
DOI
2020-03
Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer
DOI
2020-04
Prognostic role of androgen receptor expression in surgically resected early breast cancer patients
DOI
2020-04
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
DOI
2020-05
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
DOI
2020-06
Effect of timing of gonadotropin-releasing hormone agonist administration for ovarian protection in patients with breast cancer
DOI
2020-07
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
DOI
2020-07
Clinicopathological Features of Patients with the BRCA1 c.5339T > C (p.Leu1780Pro) Variant
DOI
2020-09
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
DOI
2020-10
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
DOI
2020-10
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2020-11
HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor

Chang, Hyeyeon; Shin, Yong-Won; Keam, Bhumsuk; Kim, Miso; Im, Seock-Ah; Lee, Soon-Tae

Annals of Clinical and Translational Neurology, Vol.7 No.11, pp.2243-2250

DOI
2020-12
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
DOI
2021
DNA Damage Repair Inhibitor for Breast Cancer Treatment

Min, Ahrum; Lee, Kyung-Hun; Im, Seock-Ah

Advances in Experimental Medicine and Biology, Vol.1187, pp.159-179

DOI
2021
DNA Damage Repair Inhibitor for Breast Cancer Treatment

Min, Ahrum; Lee, Kyung-Hun; Im, Seock-Ah

Advances in Experimental Medicine and Biology, Vol.1187, pp.159-179

DOI
2021-01
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
DOI
2021-01
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
DOI
2021-01
Development of a Novel Orthotopic Gastric Cancer Mouse Model
view fileDOI
2021-02
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
DOI
2021-04
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
DOI
2021-05
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1(+) Activated T Cells
DOI
2021-06
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials
DOI
2021-07
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Gelmon, Karen A.; Fasching, Peter A.; Couch, Fergus J.; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; McCutcheon, Susan; Walker, Graham; O'Shaughnessy, Joyce; Collaborating Investigator; Timcheva, Constanta; Tomova, Antoaneta; Eisen, Andrea; Lemieux, Julie; Bazan, Fernando; Bourgeois, Hugues; Chakiba, Camille; Chehimi, Mohamad; Dalenc, Florence; De La Motte Rouge, Thibault; Frenel, Jean-Sébastien; Gonçalves, Anthony; Hardy-Bessard, Anne Claire; Lamy, Regine; Levy, Christelle; Lortholary, Alain; Mailliez, Audrey; Medioni, Jacques; Patsouris, Anne; Spaeth, Dominique; Teixeira, Luis; Tennevet, Isabelle; Villanueva, Cristian; You, Benoit; Ettl, Johannes; Gerber, Bernd; Hoffmann, Oliver; Park-Simon, Tjoung-Won; Reinisch, Mattea; Tio, Joke; Wimberger, Pauline; Boer, Katalin; Ballestrero, Alberto; Bianchini, Giampaolo; Biganzoli, Laura; Bordonaro, Roberto; Cognetti, Francesco; De Laurentiis, Michelino; De Placido, Sabino; Guarneri, Valentina; Montemurro, Filippo; Naso, Giuseppe; Santoro, Armando; Zamagni, Claudio; Kim, Seung-Jin; Nakamura, Seigo; Chae, Yee Soo; Cho, Eun Kyung; Hyun, Kim Jee; Im, Seock-Ah; Lee, Keun Seok; Park, Yeon Hee; Sohn, Joo Hyuk; Byrski, Tomasz; Huzarski, Tomasz; Kukielka-Budny, Bozena; Nowecki, Zbigniew; Szoszkiewicz, Renata; Tarnawski, Rafal; Dvornichenko, Viktoria; Moiseenko, Fedor; Mukhametshina, Guzel; Poddubskaya, Elena; Popova, Ekaterina; Tarasova, Anna; Vats, Anna; Adamo, Bárbara; Conejero, Raquel Andrés; Torres, Antonio Antón; Gelpi, Judith Balmaña; Fernández, Nieves Díaz; González, Alejandro Falcón; Garcia, Juan; Lorenzo-Lorenzo, Isabel; Antón, Fernando Moreno; Santisteban, Marta; Stradella, Agostina; Huang, Chiun-Sheng; Aksoy, Sercan; Arslan, Cagatay; Artac, Mehmet; Aydiner, Adnan; Ozyilkan, Ozgur; Sezer, Emel; Armstrong, Anne; Barrett, Sophie; Borley, Annabel; Kemp, Zoe; Michie, Caroline; Mukesh, Mukesh; Perren, Timothy; Swampillai, Angela; Young, Tammy

European Journal of Cancer, Vol.152, pp.68-77

DOI
2021-07
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
DOI
2021-07
Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report
DOI
2021-07
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES
DOI
2021-08
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
DOI
2021-08
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
DOI
2021-09
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
DOI
2021-10
Corrigendum to Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
DOI
2021-10
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
DOI
2021-10
Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini's Mean Difference of Restricted Mean Survival Times

Keam, Bhumsuk; Gorobets, Olena; Vinh-Hung, Vincent; Im, Seock-Ah

Cancer Informatics, Vol.20, pp.1-9

DOI
2021-10
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)
DOI
2021-11
EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY
DOI
2021-12
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
DOI
2021-12
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
DOI
2022
Do posttraumatic stress symptoms predict trajectories of sleep disturbance and fatigue in patients with breast cancer? A parallel-process latent growth model
DOI
2022-02
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
DOI
2022-02
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
DOI
2022-03
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
DOI
2022-03
Psychiatric symptoms mediate the effect of resilience on health-related quality of life in patients with breast cancer: Longitudinal examination
DOI
2022-04
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
DOI
2022-04
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
DOI
2022-04
Radiation Response Prediction Model Based on Integrated Clinical and Genomic Data Analysis
DOI
2022-06
Trastuzumab Deruxtecan for Breast Cancer REPLY

Cortés, Javier; Im, Seock-Ah; Cathcart, Jillian

New England Journal of Medicine, Vol.386 No.24, pp.2347-2347

DOI
2022-06
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial
DOI
2022-07
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
DOI
2022-08
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2022-10
Musculoskeletal Pain and the Prevalence of Rheumatoid Arthritis in Breast Cancer Patients During Cancer Treatment: A Retrospective Study

Kim, Ju Yeon; Kim, Min Jung; Lee, Eun Bong; Kim, Tae-Yong; Lee, Kyung-Hun; Im, Seock-Ah; Park, Jin Kyun

Journal of Breast Cancer, Vol.25 No.5, pp.404-414

DOI
2022-10
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
DOI
2022-10
The Pattern of Care for Brain Metastasis from Breast Cancer Over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
DOI
2022-11
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
DOI
2022-11
Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
DOI
1 2 3 4 5 66